Autolus Therapeutics PLC logo

Autolus Therapeutics PLC - ADR

NEW
NAS:AUTL (UK)   ADR
$ 2.49 -0.2 (-7.43%) 11:08 PM EST
At Loss
P/B:
1.39
Market Cap:
$ 662.64M
Enterprise V:
$ 111.03M
Volume:
4.14M
Avg Vol (2M):
1.97M
Warning! GuruFocus detected 1 Severe warning sign with AUTL. Try a 7-Day Free Trial to check it out.
Trade In:
Volume:
4.14M
Market Cap $:
662.64M
At Loss
Avg Vol (2M):
1.97M
Enterprise Value $:
111.03M
PB Ratio:
1.39
Website SEC Filings Stock PDF
Dataset
Financial Download GuruFocus Premium Icon Manual of Stocksâ„¢

Business Description

Autolus Therapeutics PLC logo
Autolus Therapeutics PLC
NAICS : 325412 SIC : 2834
ISIN : US05280R1005
https://www.autolus.com
191 Wood Lane, The MediaWorks, London, GBR, W12 7FP

Share Class Description:

AUTL: ADR
Compare
Compare
ZYMEVERAALPNALLOTARSTBPHTYRAELVNAVXLLYELOCSE:NOVO BVRTXREGNASX:CSLSGENXKRX:207940MRNAHKSE:02269XBRU:ARGXBNTX
Traded in other countries / regions
AUTL.USA6A3A.Germany
IPO Date
2018-06-22
Description
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Financial Strength

4/10
Name Current Vs Industry Vs History
Cash-To-Debt 12.58
Equity-to-Asset 0.58
Debt-to-Equity 0.11
Debt-to-EBITDA -0.27
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.41
Distress
Grey
Safe
Beneish M-Score -2.58
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year Revenue Growth Rate 26
3-Year EBITDA Growth Rate 33.9
3-Year EPS without NRI Growth Rate 24.8
3-Year FCF Growth Rate 29.5
3-Year Book Growth Rate -45.8
Future 3-5Y EPS without NRI Growth Rate Estimate 19.42
Future 3-5Y Total Revenue Growth Rate Estimate 326.73

Momentum Rank

5/10
Name Current Vs Industry Vs History
5-Day RSI 12.09
9-Day RSI 22.5
14-Day RSI 28.98
3-1 Month Momentum % -19.36
6-1 Month Momentum % -27.37
12-1 Month Momentum % -32.16

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 13.69
Quick Ratio 13.69
Cash Ratio 12.52
Days Sales Outstanding 4.51

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -49.3
Shareholder Yield % -78.63

Profitability Rank

1/10
Name Current Vs Industry Vs History
Operating Margin % -2162.28
Net Margin % -2677.9
FCF Margin % -2037.56
ROE % -71.91
ROA % -40.16
ROIC % -175.39
3-Year ROIIC % -10598.97
ROC (Joel Greenblatt) % -209.34
ROCE % -31.79

GF Value Rank

4/10
Name Current Vs Industry Vs History
PS Ratio 57.81
PB Ratio 1.39
Price-to-Tangible-Book 1.39
EV-to-EBIT -0.56
EV-to-EBITDA -0.58
EV-to-Revenue 11
EV-to-Forward-Revenue 607.04
EV-to-FCF -0.54
Price-to-GF-Value 0.57
Price-to-Net-Current-Asset-Value 1.8
Price-to-Net-Cash 2.17
Earnings Yield (Greenblatt) % -178.57
FCF Yield % -31.03

Financials (Next Earnings Date:2025-03-14 Est.)

AUTL's 30-Y Financials
AAPL
Income Statement Breakdown FY
No Enough Data
AAPL
Balance Sheet Breakdown
No Enough Data
AAPL
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:AUTL

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Autolus Therapeutics PLC Executives

Details

GF Value: $4.36

AUTL

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 10.091
EPS (TTM) ($) -1.22
Beta 2.15
3-Year Sharpe Ratio 0.11
3-Year Sortino Ratio 0.19
Volatility % 84.07
14-Day RSI 28.98
14-Day ATR ($) 0.235965
20-Day SMA ($) 2.97675
12-1 Month Momentum % -32.16
52-Week Range ($) 2.45 - 7.45
Shares Outstanding (Mil) 266.12

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Autolus Therapeutics PLC Filings

Filing Date Document Date Form
No Filing Data

Autolus Therapeutics PLC Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

Autolus Therapeutics PLC Frequently Asked Questions

What is Autolus Therapeutics PLC(AUTL)'s stock price today?
The current price of AUTL is $2.49. The 52 week high of AUTL is $7.45 and 52 week low is $2.45.
When is next earnings date of Autolus Therapeutics PLC(AUTL)?
The next earnings date of Autolus Therapeutics PLC(AUTL) is 2025-03-14 Est..
Does Autolus Therapeutics PLC(AUTL) pay dividends? If so, how much?
Autolus Therapeutics PLC(AUTL) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.